You are currently viewing a new version of our website. To view the old version click .

Pharmaceutics, Volume 8, Issue 1

March 2016 - 9 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (9)

  • Review
  • Open Access
47 Citations
11,008 Views
8 Pages

Comprehensive Assessments of RNA-seq by the SEQC Consortium: FDA-Led Efforts Advance Precision Medicine

  • Joshua Xu,
  • Binsheng Gong,
  • Leihong Wu,
  • Shraddha Thakkar,
  • Huixiao Hong and
  • Weida Tong

Studies on gene expression in response to therapy have led to the discovery of pharmacogenomics biomarkers and advances in precision medicine. Whole transcriptome sequencing (RNA-seq) is an emerging tool for profiling gene expression and has received...

  • Review
  • Open Access
176 Citations
14,150 Views
22 Pages

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators

  • Signe Tandrup Schmidt,
  • Camilla Foged,
  • Karen Smith Korsholm,
  • Thomas Rades and
  • Dennis Christensen

The development of subunit vaccines has become very attractive in recent years due to their superior safety profiles as compared to traditional vaccines based on live attenuated or whole inactivated pathogens, and there is an unmet medical need for i...

  • Review
  • Open Access
157 Citations
12,938 Views
31 Pages

Development of Liposomal Ciprofloxacin to Treat Lung Infections

  • David Cipolla,
  • Jim Blanchard and
  • Igor Gonda

Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacte...

  • Article
  • Open Access
23 Citations
10,186 Views
13 Pages

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions

  • Johanna Weiss,
  • Thomas Gajek,
  • Bruno Christian Köhler and
  • Walter Emil Haefeli

Venetoclax (ABT-199) represents a specific B-cell lymphoma 2 (Bcl-2) inhibitor that is currently under development for the treatment of lymphoid malignancies. So far, there is no published information on its interaction potential with important drug...

  • Article
  • Open Access
24 Citations
7,422 Views
15 Pages

Cytochrome P450 drug metabolizing enzymes are implicated in personalized medicine for two main reasons. First, inter-individual variability in CYP3A4 expression is a confounding factor during cancer treatment. Second, inhibition or induction of CYP3A...

  • Article
  • Open Access
22 Citations
11,961 Views
11 Pages

Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin

  • Hui Ming Chua,
  • Nathalie Hauet Richer,
  • Magda Swedrowska,
  • Stephen Ingham,
  • Stephen Tomlin and
  • Ben Forbes

Circadin 2 mg prolonged-release tablet is the only licensed melatonin product available in the UK. Circadin is indicated for patients with primary insomnia aged 55 and over, but is more widely used “off-label” to treat sleep disorders especially in t...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceutics - ISSN 1999-4923